

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical composition comprising a first and a second antibody molecule, or a portion thereof, having the capability to bind to different epitopes located on same or different ErbB receptor molecule types, wherein said first antibody molecule or a portion thereof, comprises binding sites that bind to a first specific epitope on the ErbB1 receptor molecule type, and said second antibody molecule comprises binding sites that bind to a second specific epitope on the same ErbB1 receptor molecule type.
2. (Currently Amended) A pharmaceutical composition according to claim 1 ~~or~~ 2, wherein at least said first or said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
3. (Original) A pharmaceutical composition according to claim 1, wherein said first and said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
4. (Currently Amended) A pharmaceutical composition according to claim 2 ~~or~~ 3, wherein said receptor binding domain is the binding domain of the natural ligand of said ErbB1 receptor molecule type.
5. (Currently Amended) A pharmaceutical composition according to claim 2 ~~or~~ 3, wherein the first and second antibody, or fragment thereof, binds to different epitopes within the binding domain of the natural ligand(s) of said ErbB1 receptor molecule type.
6. (Original) A pharmaceutical composition according claims 5, wherein blocking and / or inhibition of the ErbB receptor, and induction of down-regulation of ErbB receptor-specific pathway signaling is enhanced as compared with a composition comprising a

single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.

7. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 6~~ Claim 1, wherein the induction of cross-linking and / or dimerization of ErbB receptor molecules of the same or different specificity is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
8. (Original) A pharmaceutical composition of claim 7, wherein said ErbB receptor molecules, are involved in cross-linking and / or dimerization, and are selected from ErbB1 and ErbB2 (Her-2).
9. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 8~~ Claim 1, wherein said first and / or said second antibodies is a monospecific antibody.
10. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 9~~ Claim 1, wherein the first antibody is murine, chimeric or humanized MAb 425.
11. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 9~~ Claim 1, wherein the second antibody is murine, chimeric or humanized MAb 225.
12. (Currently Amended) A pharmaceutical composition according to claim 10 ~~or 11~~, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).
13. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 12~~ Claim 1, comprising additionally a cytotoxic agent.

14. (Original) A pharmaceutical composition according to claim 13, wherein said cytotoxic agent is a chemotherapeutic agent.
15. (Original) A pharmaceutical composition according of claim 14, wherein said chemotherapeutic agent is selected from any of the compounds of the group: cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
16. (Original) A pharmaceutical composition of claim 15, wherein said cytotoxic agent is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.
17. (Currently Amended) A pharmaceutical composition according to ~~any of the claims 1 to 12~~ Claim 1, wherein said first and / or said second antibody molecule is an immunoconjugate, wherein the antibody portion is fused by its C-terminus to a biologically effective peptide, polypeptide or protein, optionally via a linker peptide.
18. (Original) A pharmaceutical composition of claim 17, wherein the protein is a cytokine.
19. (Original) A pharmaceutical kit comprising
 - (i) a first package comprising a first antibody molecule, or a portion thereof, which comprises binding sites that bind to a first specific epitope present on a ErbB1 receptor molecule, and
 - (ii) a second package comprising a second antibody molecule which comprises binding sites that bind to a second different specific epitope on the same ErbB1 receptor molecule type.
20. (Original) A pharmaceutical kit according to claim 19, wherein at least said first or said second eptitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.

21. (Original) A pharmaceutical kit according to claim 19, wherein said first and said second epitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
22. (Currently Amended) A pharmaceutical kit according to ~~any of the claims 19 to 21~~ Claim 19, wherein at least one of said molecules binds to an epitope within the ErbB1 receptor binding domain to which the natural ligand of the receptor binds.
23. (Currently Amended) A pharmaceutical kit according to ~~any of the claims 19—22~~ Claim 19, wherein said first antibody molecule is murine, chimeric or humanized monoclonal antibody 425, and said second molecule is murine, chimeric or humanized monoclonal antibody 225.
24. (Original) A pharmaceutical kit according to claim 23 comprising a first package that comprises humanized MAb 425 (h425) and a second package that comprises chimeric MAb 225 (c225).
25. (Currently Amended) A pharmaceutical kit according to ~~any of the claims 19—24~~ Claim 19 comprising additionally a third package comprising a cytotoxic agent.
26. (Original) A pharmaceutical kit according to claim 25, wherein said cytotoxic agent is a chemotherapeutic agent.
27. (Original) A pharmaceutical kit according to claim 26, wherein said chemotherapeutic agent is selected from any of the compounds of the group: cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
28. (Original) A pharmaceutical kit according claim 26, wherein said cytotoxic drug is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.

29. (Currently Amended) Use of a pharmaceutical composition or a pharmaceutical kit as defined in ~~any of the claims 1—28~~ Claim 1, for the manufacture of a medicament to treat tumors or tumor related diseases.